VolitionRX (NYSEAMERICAN:VNRX) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

VolitionRX (NYSEAMERICAN:VNRX) announced its quarterly earnings results on Monday. The medical research company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.01, Morningstar.com reports.

NYSEAMERICAN:VNRX traded up $0.08 during midday trading on Tuesday, hitting $3.99. 23,820 shares of the company were exchanged, compared to its average volume of 100,148. VolitionRX has a fifty-two week low of $1.67 and a fifty-two week high of $4.65.

In other VolitionRX news, Director Martin Charles Faulkes acquired 70,731 shares of the company’s stock in a transaction on Monday, June 10th. The shares were bought at an average cost of $3.02 per share, for a total transaction of $213,607.62. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

A hedge fund recently raised its stake in VolitionRX stock. Bank of New York Mellon Corp grew its position in VolitionRX Ltd (NYSEAMERICAN:VNRX) by 179.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,924 shares of the medical research company’s stock after acquiring an additional 18,589 shares during the period. Bank of New York Mellon Corp owned about 0.08% of VolitionRX worth $52,000 at the end of the most recent quarter.

About VolitionRX

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Featured Story: Do Tariffs Work?

Earnings History for VolitionRX (NYSEAMERICAN:VNRX)

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.